Intellipharmaceutics International Inc. (IPCIF)

Market Cap	2.43M
Revenue (ttm)	904,946
Net Income (ttm)	-3.17M
Shares Out	40.57M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	0.0600
Previous Close	0.1200
Day's Range	0.0600 - 0.0600
52-Week Range	0.0100 - 0.1400
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About IPCIF

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 11
• Stock Exchange: OTCMKTS
• Ticker Symbol: IPCIF

Financial Performance

In 2022, IPCIF's revenue was $65,728, a change of 0.00% compared to the previous year's $65,728. Losses were -$2.89 million, 0.00% compared to 2021.